Fierce Biotech Week 2026: AI & Oncology Pipeline Preview
Fierce Biotech Week 2026 is scheduled for May 12-14 in Everett, MA. The conference will likely cover key trends in drug development, with potential discussions on artificial intelligence (AI) applications and oncology pipeline updates.
Key Takeaways
- Fierce Biotech Week 2026 will take place May 12-14 in Everett, MA.
- AI applications in clinical data and statistical programming will likely be a key discussion point, based on presentations at related conferences.
- Oncology continues to be a leading therapy area in biopharmaceutical pipelines.
- Check Fierce Biotech for updates on confirmed data readouts and session details.
Fierce Biotech Week 2026 is scheduled to take place May 12-14 in Everett, MA. The conference will likely cover key trends in drug development, with potential discussions on artificial intelligence (AI) applications and oncology pipeline updates.
Fierce Biotech Week 2026 is an in-person conference focusing on various aspects of the biopharmaceutical industry, including drug development, innovation, investment, and deal-making. The event will be held at Encore Boston Harbor in Everett, MA, from May 12–14, 2026. While a detailed agenda specific to the event is not yet available, related conference presentations and recent industry news provide insights into potential topics.
AI Applications in Drug Development
Confirmed papers from related conferences, such as PharmaSUG 2026, highlight the increasing role of AI in clinical data management and statistical programming. Examples include:
- Enhancing ADaM (Analysis Data Model) specification validation using Large Language Models (LLMs).
- Vibe coding with AI coding agents in SAS, R, and Python.
- Accelerating CDISC (Clinical Data Interchange Standards Consortium) SEND (Standard for Exchange of Nonclinical Data) conversion with AI.
- AI-powered risk management in risk-based quality management (RBQM).
- Preparing health data for efficient and accurate AI and LLM modeling.
Key Biopharma Pipeline Trends
Recent data indicates that the total number of drugs in development experienced a slight decline in 2025, decreasing by 3.9% to 22,940. Oncology remains the dominant therapy area, accounting for 38.6% of new drug candidates. Roche and AstraZeneca are among the top companies based on pipeline size.
Notable Drug Developments
Recent updates in drug development include:
- Revolution Medicines: Positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer.
- GSK: Discontinuation of XMT-2056, a Mersana ADC (antibody-drug conjugate).
- Merck: Anticipated Phase 3 readouts in 2026 for islatravir + lenacapavir, tulisokibart, and MK-3000.
- AstraZeneca: Phase 2 TRAVERSE trial of Calquence (acalabrutinib) + Venclexta (venetoclax) + rituximab in mantle cell lymphoma is part of an FDA real-time data pilot program.
Market & Investor Implications
Early-stage funding in the biotech sector saw a decrease in Q1 2026 compared to the previous year, with 50 seed/Series A deals totaling $2.3 billion, down from $3.7 billion in Q1 2025.
What to Watch Next
Monitor Fierce Biotech for updates on confirmed data readouts, specific session details, and any late-breaking abstracts related to Fierce Biotech Week 2026.
Frequently Asked Questions
- When and where is Fierce Biotech Week 2026 being held?
- Fierce Biotech Week 2026 will be held May 12–14, 2026, at Encore Boston Harbor, Everett, MA.
- What are some potential topics to be discussed at the conference?
- Based on related conference presentations, expect discussions on AI applications in clinical data, ADaM specs, and statistical programming. Other topics include emerging therapeutic modalities, gene and cell therapy, and biopharma R&D strategy.
- Which therapy area is currently leading in biopharma pipelines?
- Oncology continues to lead as the top therapy area for new drug candidates.
- Are there any specific data readouts confirmed for the event?
- As of now, no specific data readouts have been confirmed. Check official Fierce Biotech updates for the latest information.
- What recent drug development news might be relevant to the conference?
- Notable developments include Revolution Medicines' positive data for daraxonrasib, GSK's discontinuation of XMT-2056, and Merck's upcoming Phase 3 readouts for islatravir + lenacapavir, tulisokibart and MK-3000.
